• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    ZeroStack Corp. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    5/6/26 4:01:33 PM ET
    $ZSTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZSTK alert in real time by email
    ZeroStack Corp.: Form 8-K - Filed by newsfilecorp.com

    false 2026-05-05 0001790169 00-0000000 ZeroStack Corp. 0001790169 2026-05-05 2026-05-05

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    ___________________________

    FORM 8-K

    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 5, 2026

    ZEROSTACK CORP.
    (Exact name of registrant as specified in its charter)

    Ontario 001-40397 Not Applicable
    (State or other jurisdiction (Commission (IRS Employer
    of incorporation) File Number) Identification No.)

    40 King Street West, Suite 2400
    Toronto, Ontario, Canada M5H 3Y2
    (Address of principal executive offices) (ZIP Code)

    Registrant’s telephone number, including area code: (954) 842-4989

    Not Applicable
    (Former name or former address, if changed since last report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class   Trading Symbols   Name of each exchange on which registered
    Common Shares, no par value   ZSTK   NASDAQ Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b -2 of this chapter).

    Emerging growth company ☑

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

    On May 5, 2026, the independent members of the board of directors (the "Board") of ZeroStack Corp. (the "Company") granted (i) 500,000 stock options to Daniel Reis-Faria, Chief Executive Officer of the Company (the "Reis-Faria Options"), (ii) 250,000 stock options to Mr. Dany Vaiman, Chief Financial Officer of the Company (the "Vaiman Options") and (iii) 500,000 stock options to Mr. Michael Heinrich, the Executive Chairman of the Board (the "Heinrich Options" and together with the Reis-Faria Options and Vaiman Options, the "Stock Options").

    The Stock Options are (a) unexercisable until seven calendar days after the closing of the transactions contemplated by the Share Exchange Agreement by and among the Company, Texas Blocker Corp. and stockholders of Texas Blocker Corp. named on Schedule A thereto and (b) subject to forfeiture, unless the Company's shareholders approve the grant of Stock Options at the Company's annual and special meeting of shareholders to be held on or about July 13, 2026.

    The Stock Options will be exercisable at $5.10 per share and have a term of 10 years from issuance. The Stock Options will vest based on the volume weighted average price of the Company's Common Shares as follows:

    Percentage of Options Vested At or above the following VWAP on any trading day
    20% $7.65
    20% $10.20
    20% $12.75
    20% $15.30
    20% $17.85

    The Form of Stock Option Agreement for the Stock Options is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. The description of the Stock Options in this Current Report on Form 8-K is only a summary and is qualified in its entirety by reference to the actual terms of the Form of Stock Option Agreement.

    Item 9.01. Exhibits.

    Exhibit Description
    10.1 Form of Stock Option Agreement, dated May 5, 2026
    104 Cover Page Interactive Data File (embedded within the Inline XBRL document)


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

      ZEROSTACK CORP.
      (Registrant)
       
    Dated: May 6, 2026  
      By: /s/ Dany Vaiman
      Dany Vaiman
      Chief Financial Officer


    Get the next $ZSTK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZSTK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ZSTK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Chairman Heinrich Michael bought $3,479,013 worth of shares (4,608,575 units at $0.75) (SEC Form 4)

    4 - ZeroStack Corp. (0001790169) (Issuer)

    7/20/26 6:31:03 PM ET
    $ZSTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Reis-Faria Daniel exercised 5,954,743 in-the-money shares at a strike of $0.00 (SEC Form 4)

    4 - ZeroStack Corp. (0001790169) (Issuer)

    7/20/26 6:26:15 PM ET
    $ZSTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CFO Vaiman Dany

    4 - ZeroStack Corp. (0001790169) (Issuer)

    7/20/26 6:21:25 PM ET
    $ZSTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZSTK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Chairman Heinrich Michael bought $3,479,013 worth of shares (4,608,575 units at $0.75) (SEC Form 4)

    4 - ZeroStack Corp. (0001790169) (Issuer)

    7/20/26 6:31:03 PM ET
    $ZSTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZSTK
    SEC Filings

    View All

    ZeroStack Corp. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - ZeroStack Corp. (0001790169) (Filer)

    7/20/26 4:02:11 PM ET
    $ZSTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by ZeroStack Corp.

    EFFECT - ZeroStack Corp. (0001790169) (Filer)

    6/18/26 12:15:34 AM ET
    $ZSTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by ZeroStack Corp.

    424B3 - ZeroStack Corp. (0001790169) (Filer)

    6/17/26 4:53:30 PM ET
    $ZSTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZSTK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ZeroStack Announces Results of 2026 Annual and Special Meeting of Shareholders, Provides Phatebo Purchase Orders Update and Announces Closing of Previously Announced Cryptocurrency Financing

    Dallas, Texas--(Newsfile Corp. - July 20, 2026) - ZeroStack Corp. (NASDAQ:ZSTK) ("ZeroStack" or the "Company"), the first Nasdaq-listed, AI-focused asset management company, held its 2026 Annual and Special Meeting of Shareholders (the "Meeting"). The final voting results of the proposals submitted to a vote of the Company's shareholders at the Meeting are as follows: Proposal 1: Election of five directors to the board of directors of the Company (the "Board") to hold office until the Company's 2027 Annual Meeting of Shareholders or until their respective successors are duly elected and qualified. If Proposal 7 is approved, the Board will be staggered as described in the proxy statement/pros

    7/20/26 4:01:00 PM ET
    $ZSTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ZeroStack Corp. Secures Purchase Orders for up to US$14.7 Million of Inventory from Two Pharmaceutical Companies

    Toronto, Ontario--(Newsfile Corp. - July 9, 2026) - ZeroStack Corp. (NASDAQ:ZSTK) (the "Company" or "ZeroStack"), the first Nasdaq-listed, AI-focused asset management company, today announced that it has secured pharmaceutical distribution purchase orders for up to approximately US$14.7 million (EUR 12.9 million) of inventory in Germany from two companies (the "Orders"). The Orders are expected to be fulfilled through the Company's wholly owned German subsidiary, Phatebo GmbH ("Phatebo").Phatebo has operated as a pharmaceutical distributor in Europe for more than then years and serves as the Company's primary operating subsidiary. In connection with ZeroStack's long-term strategy, Phatebo co

    7/9/26 8:01:00 AM ET
    $ZSTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DeFi Dev Corp. Announces Strategic Leadership Transition of DisclaimerCoin (DONT) to Dedicated Ecosystem Team

    BOCA RATON, FL, July 08, 2026 (GLOBE NEWSWIRE) -- DeFi Development Corp. (NASDAQ:DFDV) (the "Company"), the first U.S. public company with a treasury strategy built to accumulate and compound Solana ("SOL"), today announced the strategic transition of leadership for DisclaimerCoin ("DONT"), the world’s first publicly traded company-created memecoin, to Daniel Reis-Faria, Chief Executive Officer of Nasdaq-listed ZeroStack Holdings Inc. (NASDAQ:ZSTK), and a dedicated team focused exclusively on growing the DisclaimerCoin ecosystem. The transition represents the next phase in DisclaimerCoin’s evolution. While DFDV pioneered the historic launch of DONT in January 2026, the Company believes th

    7/8/26 9:00:00 AM ET
    $DFDV
    $ZSTK
    Finance: Consumer Services
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZSTK
    Leadership Updates

    Live Leadership Updates

    View All

    DeFi Dev Corp. Announces Strategic Leadership Transition of DisclaimerCoin (DONT) to Dedicated Ecosystem Team

    BOCA RATON, FL, July 08, 2026 (GLOBE NEWSWIRE) -- DeFi Development Corp. (NASDAQ:DFDV) (the "Company"), the first U.S. public company with a treasury strategy built to accumulate and compound Solana ("SOL"), today announced the strategic transition of leadership for DisclaimerCoin ("DONT"), the world’s first publicly traded company-created memecoin, to Daniel Reis-Faria, Chief Executive Officer of Nasdaq-listed ZeroStack Holdings Inc. (NASDAQ:ZSTK), and a dedicated team focused exclusively on growing the DisclaimerCoin ecosystem. The transition represents the next phase in DisclaimerCoin’s evolution. While DFDV pioneered the historic launch of DONT in January 2026, the Company believes th

    7/8/26 9:00:00 AM ET
    $DFDV
    $ZSTK
    Finance: Consumer Services
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care